217 related articles for article (PubMed ID: 19091547)
41. Trends in endpoint selection in clinical trials of advanced breast cancer.
Song SY; Seo H; Kim G; Kim AR; Kim EY
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2403-13. PubMed ID: 27586374
[TBL] [Abstract][Full Text] [Related]
42. Alternate endpoints for screening phase II studies.
Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
[TBL] [Abstract][Full Text] [Related]
43. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study.
Greene T; Teng CC; Inker LA; Redd A; Ying J; Woodward M; Coresh J; Levey AS
Am J Kidney Dis; 2014 Dec; 64(6):867-79. PubMed ID: 25441440
[TBL] [Abstract][Full Text] [Related]
44. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Sharma MR; Gray E; Goldberg RM; Sargent DJ; Karrison TG
J Clin Oncol; 2015 Jan; 33(1):36-41. PubMed ID: 25349295
[TBL] [Abstract][Full Text] [Related]
45. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.
Prasad V; Kim C; Burotto M; Vandross A
JAMA Intern Med; 2015 Aug; 175(8):1389-98. PubMed ID: 26098871
[TBL] [Abstract][Full Text] [Related]
46. RECIST - learning from the past to build the future.
Litière S; Collette S; de Vries EG; Seymour L; Bogaerts J
Nat Rev Clin Oncol; 2017 Mar; 14(3):187-192. PubMed ID: 27995946
[TBL] [Abstract][Full Text] [Related]
47. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.
Badve SV; Palmer SC; Hawley CM; Pascoe EM; Strippoli GF; Johnson DW
Nephrol Dial Transplant; 2016 Sep; 31(9):1425-36. PubMed ID: 26163881
[TBL] [Abstract][Full Text] [Related]
48. Practice and progress in kidney cancer: methodology for novel drug development.
Rini BI; Weinberg V; Small EJ
J Urol; 2004 Jun; 171(6 Pt 1):2115-21. PubMed ID: 15126769
[TBL] [Abstract][Full Text] [Related]
49. Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.
Studer SM; Gilkin RJ
Am J Manag Care; 2014 Mar; 20(6 Suppl):S115-22. PubMed ID: 24716456
[TBL] [Abstract][Full Text] [Related]
50. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.
Haslam A; Hey SP; Gill J; Prasad V
Eur J Cancer; 2019 Jan; 106():196-211. PubMed ID: 30528804
[TBL] [Abstract][Full Text] [Related]
51. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
52. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article.
Wildiers H; Mauer M; Pallis A; Hurria A; Mohile SG; Luciani A; Curigliano G; Extermann M; Lichtman SM; Ballman K; Cohen HJ; Muss H; Wedding U
J Clin Oncol; 2013 Oct; 31(29):3711-8. PubMed ID: 24019549
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society.
Husband JE; Schwartz LH; Spencer J; Ollivier L; King DM; Johnson R; Reznek R;
Br J Cancer; 2004 Jun; 90(12):2256-60. PubMed ID: 15150551
[TBL] [Abstract][Full Text] [Related]
54. Adapting the sample size planning of a phase III trial based on phase II data.
Wang SJ; Hung HM; O'Neill RT
Pharm Stat; 2006; 5(2):85-97. PubMed ID: 17080765
[TBL] [Abstract][Full Text] [Related]
55. Key issues in end point selection for heart failure trials: composite end points.
Neaton JD; Gray G; Zuckerman BD; Konstam MA
J Card Fail; 2005 Oct; 11(8):567-75. PubMed ID: 16230258
[TBL] [Abstract][Full Text] [Related]
56. Monitoring event times in early phase clinical trials: some practical issues.
Thall PF; Wooten LH; Tannir NM
Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
[TBL] [Abstract][Full Text] [Related]
57. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?
Ohorodnyk P; Eisenhauer EA; Booth CM
Eur J Cancer; 2009 Sep; 45(13):2249-52. PubMed ID: 19545996
[TBL] [Abstract][Full Text] [Related]
58. Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.
Dercle L; Connors DE; Tang Y; Adam SJ; Gönen M; Hilden P; Karovic S; Maitland M; Moskowitz CS; Kelloff G; Zhao B; Oxnard GR; Schwartz LH
JCO Clin Cancer Inform; 2018 Dec; 2():1-12. PubMed ID: 30652552
[TBL] [Abstract][Full Text] [Related]
59. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant and adjuvant end-points in health technology assessment in oncology.
Harbeck N; Schneeweiss A; Thuss-Patience P; Miller K; Garbe C; Griesinger F; Eberhardt WEE; Klussmann JP; Wollenberg B; Grimm MO; Zander T; Lüftner D
Eur J Cancer; 2021 Apr; 147():40-50. PubMed ID: 33611103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
